Therapeutics Allocation & Requests

Thank you for your role in supporting access to therapeutics in Oregon. The Oregon Health Authority (OHA) appreciates your partnership as we continue navigating the federal allocation process.

Federal Allocations

Week of August 1st:

Provider Updates

• Bebtelovimab is expected to be commercially available for purchase starting the week of August 15th, 2022 
  • Once commercially available, providers would be able to order directly through commercial distributers  
  • Reporting inventory and utilization in HPOP is still highly encouraged. If you do not report inventory and utilization, your site will no longer appear on the federal locator 
  • Having accurate information on the COVID-19 Therapeutics Locator helps ensure equitable access to therapeutics across Oregon 

• The Oregon Health Authority has limited stock of Bebtelovimab and is able to continue distribution of the product to Oregon providers until stock is depleted  
  • OHA is committed to equitable distribution of the limited stock that remains 
  • OHA may not be able to fulfill 100% of the courses requested for all providers. Providers who receive OHA supply must continue to report inventory and utilization in HPOP 
• On July 6th, 2022, the FDA updated the EUA for Paxlovid to allow for pharmacist prescribing for individual patients with certain limitations. 
  • With this recent change in the Paxlovid EUA, Oregon-licensed pharmacists now have liability immunity and scope of authority to prescribe Paxlovid under the 9th amendment of the Department of Health and Human Services Public Readiness and Emergency Preparedness Act (PREP). Pharmacy interns and technicians cannot prescribe Paxlovid under the PREP Act because the Paxlovid EUA only authorizes pharmacists to prescribe Paxlovid. Pharmacists must adhere to the EUA and the PREP Act when prescribing Paxlovid, including all documentation and patient follow-up required under the EUA and PREP Act. 

• FDA authorizes revisions to Evusheld re-dosing and Evusheld shelf life extensions. 
• The AstraZeneca Call Center remains available should providers have questions regarding the updated dosing guidance and/or the shelf-life extension for Evusheld. The AstraZeneca Call Center can be reached at 1-800-236-9933
• Evusheld can now be directly ordered in small quantities for individual providers through this form: OrderEvusheld.com 

• Evusheld is now available at some Federally Registered Pharmacy Partners for patients with an Evusheld prescription  

  • Please check the COVID-19 Therapeutics Locator to find pharmacies that have Evusheld 
  • Please call ahead to ensure services are available  
• OHA has launched the new COVID-19 Therapeutics Newsletter! Please click the link to view the July edition for COVID-19 therapeutics updates, allocation data, events and more. Our newsletters will be sent out monthly and can be found under the "Additional Resources" section on our webpages. Please feel free to share.

• The federal government has released the Test to Treat Locator to make it easier to find Test to Treat (T2T) sites and where to send prescriptions to.  
  • IMPORTANT: Please check the locator periodically as sites continue to be added. 

• OHA has launched our new COVID-19 Therapeutics Newsletter! Please click the link to view the June edition for COVID-19 therapeutics updates, allocation data, events and more. Our newsletters will be sent out monthly and can be found under the "Additional Resources" section on our webpages.
• For additional guidance on the new ordering process, cadence, and reporting utilization, please review our Provider Operations Manual. 
• Please visit our COVID-19 Therapeutics Landing Page  for information and resources on mAbs and antivirals. 
• For all questions or inquiries, please email us at OHA.Therapeutics@odhsoha.oregon.gov.
• For additional federal updates, shelf-life extensions, and more, please visit the ASPR webpage and the ASPR COVID-19 Therapeutics Videos. 

Placing Requests

• All orders are to be placed via the Health Partner Ordering Portal (HPOP).  
• If you are a new provider site and have not signed up to receive therapeutics via Oregon Health Authority, please complete the Complete the COVID-19 Therapeutics Provider Registration Survey. 

Product Case Size 

Each product has a specific case size and is outlined below. When ordering, please consider the case size and order accordingly to ensure OHA can fulfill your requests properly.  

• Evusheld - 24 cases 
• Bebtelovimab - 5 cases 
• Paxlovid - 20 courses 
• Renal Paxlovid - 5 courses 
• Lagevrio (molnupiravir) - 24 courses 

Allocation 

For information on mAbs allocation process, and to view published federal allocation amounts, please visit: OHA's Monoclonal Antibody Webpage 

For information on oral antivirals allocation process, and to view published federal allocation amounts, please visit:  OHA's Antiviral Webpage 

Cadence 

• Monday - HHS notifies Oregon of our total therapeutics allotment.

NOTE: HHS informs Oregon of  Evusheld’s total allotment monthly, every 4th Monday   

• Wednesday - Orders received by 11:59 p.m. will be allocated for the current week  
• Thursday/Friday - OHA staff will review the requests, determine allotments for each requesting site, and process via the Health Partner Ordering Portal (HPOP) by Friday.

NOTE: AmerisourceBergen anticipates shipping the products within 3-5 days of order submission. 

Utilization reporting 

Utilization reporting is a key component that HHS takes into consideration when determining each state’s allotment. Therefore, it is crucial that each site report their utilization twice a week on Mondays and Thursdays by 11:59pm, including for any product redistributed to other sites. Under-utilization in HPoP and under-reporting will affect Oregon’s future allocations. 

Track your shipment 

Once your packages are shipped by Amerisource Bergen, you can track them using Track My Shipment Tool.  

For oral antivirals shipment tracking, please visit your HPOP account and reference "Therapeutic Shipping." 

Thank you, 

Oregon Health Authority